TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Firebrick Pharma Limited ( (AU:FRE) ) has shared an update.
Firebrick Pharma Limited has announced a change in its auditing firm, transitioning from BDO Audit Pty Ltd to Criterion Audit Pty Ltd effective December 1, 2025. This change aims to align audit services with the company’s size and nature, resulting in cost reductions. The appointment of the new auditor will be ratified at the next Annual General Meeting in November 2026.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has introduced Nasodine® Nasal Spray into markets such as the United States, Singapore, and Fiji & South Pacific, with further expansion expected in the Philippines in 2026. Additionally, Firebrick is preparing to launch Nasodine Throat Spray in Singapore.
Average Trading Volume: 92,051
Technical Sentiment Signal: Sell
Current Market Cap: A$15.6M
For an in-depth examination of FRE stock, go to TipRanks’ Overview page.